Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Cancer is the second leading cause of death globally, trailing only heart disease. In the
United States alone, 1.9 million new cancer cases and 609,360 deaths were recorded for …

Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …

Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …

The inefficiency of existing animal models to precisely predict human pharmacological
effects is the root reason for drug development failure. Microphysiological system/organ-on …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

To achieve the scheme of “magic bullets” in antitumor therapy, antibody-drug conjugates
(ADCs) were developed. ADCs consist of antibodies targeting tumor-specific antigens …

In women, cervical cancer (CC) is the fourth most common cancer around the world with
average cases of 604,000 and 342,000 deaths per year. Approximately 50% of high-grade …

Endometrial cancer (EC) is the 6th most common cancer in women around the world. Alone
in the United States (US), 66,200 new cases and 13,030 deaths are expected to occur in …

Advancements in data acquisition and computational methods are generating a large
amount of heterogeneous biomedical data from diagnostic domains such as clinical …